A 5-Question Quiz on Ovarian Cancer

August 1, 2017

Do you know how many new cases of ovarian cancer will be diagnosed this year in the United States? Or which tumor marker is used to follow granulosa cell ovarian cancers? Take this quiz to test your knowledge on the management of ovarian cancer.

Do you know how many new cases of ovarian cancer will be diagnosed this year in the United States? Or which tumor marker is used to follow granulosa cell ovarian cancers? Take this quiz to test your knowledge on the management of ovarian cancer.

Question 1

Answer and Question 2 on Next Page »

Answer

B. 22,440. According to the American Cancer Society, it is also estimated that this year, 12,820 women will be diagnosed with cancers of the cervix, 61,380 with cancers of the uterine corpus, and 10,830 with cancers of the vulva and vagina.

Question 2

Answer and Question 3 on Next Page »

Answer

C. Inhibin. One study found that inhibin A and B concentrations in the blood were elevated in 67% and 89% of patients with granulosa cell tumors at diagnosis, respectively, and in 58% and 85% of patients at recurrence.

Question 3

Answer and Question 4 on Next Page »

Answer

D. Compared to BRCA1 mutations, BRCA2 mutations have a higher risk of ovarian cancer. A recent study found that the cumulative ovarian cancer risk to age 80 years to be 44% for BRCA1 carriers and 17% for BRCA2 carriers.

Question 4

Answer and Question 5 on Next Page »

Answer

B. 14,080. According to the American Cancer Society, it is also estimated that 4,210 women will die this year in the United States from cancers of the cervix, 10,920 from cancers of the uterine corpus, and 2,390 from cancers of the vulva and vagina.

Question 5

Answer on Next Page »

Answer

A. Cediranib. Maintenance therapy with chemotherapy and cediranib was associated with a median time from diagnosis to death of 51.3 months, compared with 43.3 months for chemotherapy and placebo, according to the study.